Evidence-based vancomycin dosing,
calculated in seconds.

What is a vancomycin calculator?

A vancomycin calculator is a clinical pharmacokinetics tool that estimates the correct loading dose, maintenance dose, and dosing interval for vancomycin therapy based on individual patient characteristics. Vancomycin is a glycopeptide antibiotic used primarily to treat serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive pathogens, and its narrow therapeutic index makes individualized dosing essential.

This tool uses the AUC-based dosing approach recommended by the 2020 joint guidelines from the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). It estimates creatinine clearance via the Cockcroft-Gault equation and calculates pharmacokinetic parameters including volume of distribution, elimination rate constant, and 24-hour area under the curve (AUC₂₄).

Whether you're a clinical pharmacist reviewing dosing for a hospitalized patient, a physician estimating initial therapy, or a pharmacy student studying pharmacokinetics, this vancomycin dosing calculator gives you a rapid, evidence-based starting point before therapeutic drug monitoring (TDM) confirms steady-state levels.

For a deeper look at why dosing changed in 2020, see our guide on trough-based vs. AUC-based vancomycin monitoring. If your patient has impaired renal function, our renal dosing guide explains how CrCl thresholds drive interval selection.

Using the calculator & understanding the math

Vancomycin dosing guide: what clinicians need to know

Why AUC-Based Monitoring Replaced Trough-Only Dosing

For decades, clinicians monitored vancomycin therapy using a single pre-dose trough target of 15–20 mg/L. The 2020 ASHP/IDSA guidelines changed this. Trough-only monitoring was associated with higher rates of nephrotoxicity, particularly when troughs were maintained aggressively above 15 mg/L, without proportionally better clinical outcomes. The problem is that trough concentration alone doesn't describe the full drug exposure a patient receives; two patients with identical troughs can have very different 24-hour AUCs depending on their renal clearance and dosing frequency.

The target is now an AUC/MIC ratio ≥ 400 mg·h/L (assuming an MIC of 1 mg/L for MRSA, which gives AUC₂₄ ≥ 400 mg·h/L). The therapeutic window is 400–600 mg·h/L: below 400 risks therapeutic failure; above 600 correlates with nephrotoxicity. For details on how the paradigm shifted, see our article on trough vs. AUC monitoring.

Renal Dosing Adjustments for Vancomycin

Vancomycin is almost entirely renally eliminated. As CrCl declines, half-life extends dramatically, from roughly 6 hours in patients with normal renal function (CrCl ≥ 90) to 30–200+ hours in anuric patients. This is why this calculator stretches the dosing interval as CrCl falls, rather than simply reducing the dose.

For patients with CrCl < 20 mL/min, a q48h interval is the floor, and some clinicians use even longer intervals. Patients on intermittent hemodialysis require completely different dosing strategies, typically dosed after each dialysis session based on post-dialysis levels. Continuous renal replacement therapy (CRRT) requires specialized dosing that's beyond this calculator's scope. Our vancomycin renal dosing guide covers these special cases in depth.

When to Order Therapeutic Drug Monitoring

TDM is not optional for vancomycin; it's mandated by the guidelines for all patients receiving more than 48 hours of therapy. The preferred approach is two-level AUC estimation (one trough plus one mid-interval or peak level), fed into Bayesian software to generate a patient-specific AUC estimate. Single-trough-to-AUC conversion is acceptable if Bayesian tools aren't available, using published population PK equations. Draw levels after the 3rd or 4th dose in patients with stable renal function. For our full guide, see therapeutic drug monitoring in practice.

Vancomycin and Nephrotoxicity

Vancomycin-associated nephrotoxicity (VAN) occurs in 5–43% of patients in published studies, with wide variation depending on patient risk factors and monitoring approach. The AUC₂₄ > 600 mg·h/L zone correlates with significant nephrotoxicity risk, which is precisely why the upper bound of the therapeutic window is capped there. Risk increases substantially when vancomycin is combined with other nephrotoxins, particularly piperacillin-tazobactam (though this combination's nephrotoxicity is debated in recent literature) and aminoglycosides. Baseline renal function, ICU admission, and diabetes are patient-level risk factors. Monitor serum creatinine every 48–72 hours during therapy, and recalculate dosing if CrCl changes by more than 15–20%. Our nephrotoxicity prevention guide explains monitoring strategies in full.

Who should use this calculator?

Designed for healthcare professionals and clinical students who need a rapid, evidence-based starting estimate for vancomycin therapy. Here's who finds it most useful:

Not a substitute for clinical judgment, institutional protocols, or Bayesian software for high-risk patients. Always involve a clinical pharmacist for rapidly changing renal function, obesity (BMI > 40), or concomitant nephrotoxins. See our guide on vancomycin dosing in obese patients.